Therapeutic efficiency "monklavit-1 " and "rificiklin " when dyspepsia in calves and their effect on the thyroid gland

The experiment was performed on calves of black and motley breed. Two experimental groups of animals were formed, 25 individuals each, patients with dyspepsia and one intact group, which included healthy animals. Determination of sensitivity to the vaccine and the Monklavit-1 solution was carried out using the diffusion method, using disks and serial dilutions. All animals were treated comprehensively using Ringer's solutions and 5% glucose, sodium thiosulfate, procaine blockade according to V.V. Mosin, pancreatin, vetoma 1.1., Diet. The animals of the 1st experimental group used 7 g of an animal for an animal, 2 times a day, 7 days, per oral; animals of the 2nd experimental group -“Monklavit-Г, 50 ml each, per head, 2 times a day, per oral. The concentration of free thyroxin (St. T4), total triiodothyronine (vol. T3) and thyroid-stimulating hormone (TSH) was determined by the method of solid-phase immunoassay using the Alkor Bio reagents (St. Petersburg, Russia). In operation, the experimental effectiveness of Monklavit-1 in dyspepsia in calves, as well as an assessment of the effect of iodophor on the functional activity of the thyroid gland, was shown. In calves, which, as etiotropic treatment of dyspepsia, “Monklavit-1” was used, by 2, 4 and 6 days a significant increase in concentrations was ob served. T3 and St. T4, respectively, by 5% -11% (P>0.990) and 16% -20% (P>0.999) against the background of an unreliable decrease in the concentration of TSH by 8-19% relative to the pretreatment indexes. With the use of rificlin, depression of the functional activity of the thyroid gland was noted, which was manifested in a significant decrease in the concentration of St. T4 and about T3 for 18-27% (Р>0.999) and 8-17% (Р>0.999) relative to the initial values. The use of the preparation in a production environment is economically justified and recommended by us as a means of primary choice in the treatment of digestive disorders, the prevention of iodine deficiency conditions.

Монклавит-1, рифициклин, йод, тироксин, трийодтиронин, тиреотропный гормон, диспепсия, Monklavit-1, riphiciklin, iodine, thyroxine, triiodothyronine, thyroid stimulating hormone, dyspepsia

1. Васильев, Р.О. Сравнительные фармакотоксикологические и радиозащитные свойства Монклавита-1 (щитовидная железа, острые расстройства пищеварения, острая лучевая болезнь у животных): Монография / Р.О. Васильев, Е.И. Трошин, ТА Трошина, Ижевск: ФГБОУ ВО Ижевская ГСХА, 2016.

2. Герцева, К.А. Сравнительная эффективность лечебных мероприятий при алиментарной диспепсии у телят / К.А. Герцева, B.В. Сазонова // В сборнике: Инновационные подходы к развитию агропромышленного комплекса региона. Материалы 67-ой Международной научно-практической конференции. ФГБОУ ВО РГАУ им. П.А. Костычева, 2016. - С. 160-163.

3. Сапа, В.А. Итоги лечения и профилактики диспепсии телят / В.А. Сапа // Научная дискуссия: инновации в современном мире. - 2016. -№ 16(59). - С. 147-150.

4. Шантыз, А.Х. Определение антибактериальной активности нового йодсодержащего препарата / А.Х. Шантыз, П.В. Мирошнеченко, Л.Д. Хайруллин // Ученые записки Казанской государственной академии ветеринарной медицины им. Н.Э. Баумана, 2014. - Т. 220. - № 4. - С. 231-234.

5. Шепелева, Т.А. Особенности лечения токсической диспепсии телят в биогеохимической провинции южного Урала / Т.А. Шепелева // В сборнике: Инновационные подходы в ветеринарной и зоотехнической науке и практике. Материалы международной научнопрактической интернет-конференции. - 2016. - C. 155-158.